Renal Cell Carcinoma

Treatment with pembrolizumab and bevacizumab proved to be a promising combination regimen for patients with metastatic renal cell carcinoma, according to phase Ib/II data presented at the 2018 ASCO Annual Meeting.

Mario Snzol, MD, discusses the latest developments with immunotherapy, which he says is poised to become the standard of care in the treatment of patients with metastatic RCC.

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discussed the results from these 2 analyses in this high-risk patient population with RCC compared to metastatic RCC. He also shares his own insights on what to take away from this data.

Kidney Cancer

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Brian I. Rini, MD, professor of medicine at the Cleveland Clinic, discusses the rationale for combining atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma in the IMmotion151trial.

Sunitinib alone was noninferior for median overall survival compared with sunitinib plus cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma, according to findings from the phase III noninferiority CARMENA trial.

Arjun V. Balar, MD, Editor-in-Chief of Targeted Therapies in Oncology, discusses the plenary session at. the 2018 ASCO Annual Meeting. Findings from the CARMENA trial in metastatic clear cell renal cell carcinoma were presented.